$ANIP News

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals (NASDAQ:ANIP) Tumbles on Weak Guidance Despite Q2 EPS Beat

ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est

ANI Pharmaceuticals Q2 Adj. EPS $2.21 Beats $2.05 Estimate, Sales $266.044M Beat $260.128M Estimate

ANI Pharmaceuticals: The Market Is Pricing The Present, Not The Future

Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

ANI Pharmaceuticals Reveals Trial Court Denied Company’s Motion For A New Trial And Judgment As A Matter Of Law For Unjust Enrichment; Co. Intends To Appeal Rulings To The Delaware Supreme Court And Continue To Seek To Recover The Value Of The Assets It Sold To CG Oncology In 2010

ANI Pharmaceuticals Announces Topline Data From Its Phase 4 SYNCHRONICITY Clinical Trial Of The Fluocinolone Acetonide Intravitreal Implant; Trial Met Both Co-Primary Endpoints

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple

ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

ANI Pharmaceuticals (NASDAQ:ANIP) Crushes Q1 Estimates, Raises Full-Year Guidance

ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 Est; Raises FY2026 Sales Guidance from $1.055B-$1.115B to $1.080B-$1.140B vs $1.050B Est.

ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate.

ANI Pharmaceuticals Announces Launch Of Pimozide Tablets 1 Mg And 2 Mg, Generic Version Of Reference Listed Drug Orap, With 180-Day CGT Exclusivity